# Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms

> **NCT05637671** · PHASE3 · UNKNOWN · sponsor: **Cairo University** · enrollment: 146 (estimated)

## Conditions studied

- Vasomotor Symptoms

## Interventions

- **DRUG:** oxybutynin ER
- **DRUG:** Paroxetine CR

## Key facts

- **NCT ID:** NCT05637671
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-10
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05637671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05637671, "Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05637671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*